Argent BioPharma (ASX:RGT) has executed a deed of variation with Mercer Street Global Opportunity Fund to amend the terms of its 2020 convertible securities agreement, according to a Wednesday filing with the Australian bourse.
The adjustment involves refinancing 300,000 convertible notes, worth AU$1.1 million, reducing the minimum conversion price to not less than AU$0.11 from not less than AU$10, the filing said.
The company also plans to negotiate further amendments to the remaining 2020 and 2022 convertible note facilities, the filing added.
Shares of the company fell 6% in recent Wednesday trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。